echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JAMA Intern Med: Impact of SGLT-2 Inhibitors vs. Sulfonylureas on the Risk of Death in Patients with Type II Diabetes

    JAMA Intern Med: Impact of SGLT-2 Inhibitors vs. Sulfonylureas on the Risk of Death in Patients with Type II Diabetes

    • Last Update: 2021-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    SGLT2 inhibitors are a new class of antihyperglycemic drugs mechanism, which reduces type II diabetes patients with poor cardiac vascular risk and renal events


    Diabetes, heart blood vessels metformin Recently researchers compared the effects of SGLT2 inhibitors and sulfonylureas in patients with type II diabetes, all-cause mortality


    This study used data from the US veterans database to investigate the use of SGLT2 inhibitors and sulfonylureas in patients with type II diabetes on the basis of metformin treatment


    The average age of the participants was 64.


    Compared with sulfonylurea drugs, the use of SGLT2 inhibitors is associated with a reduction in all-cause mortality of patients (hazard ratio [HR]=0.


    Studies believe that compared with sulfonylureas, the use of metformin-SGLT-2 inhibitor combination therapy can reduce the risk of all-cause death in patients with type II diabetes


    Compared with sulfonylureas, combined treatment with metformin-SGLT-2 inhibitors can reduce the risk of all-cause death in patients with type II diabetes.


    Original source:

    Yan Xie et al.


    Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabete.
    JAMA

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.